Latest research

Pain, fatigue, depression and anxiety are common in established MS; this study monitored the symptoms during the first year after diagnosis of MS.

There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.

Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.

Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.

NHS England has agreed that Mayzent can be prescribed for people with active secondary progressive multiple sclerosis whose disability has increased for at least 6 months, unrelated to relapses, and while taking a disease modifying drug.

Researchers have investigated whether the benefits of early treatment, which are well-established for disease modifying drugs, could also be applied to exercise therapy.

Multiple sclerosis and Epstein-Barr virus have been in the news with reports of new avenues for treatment. But how quickly might we see new treatments or cures?

Vumerity (diroximel fumarate) has been approved by NICE for people with active relapsing remitting multiple sclerosis.

People with MS can get effective treatments if they get Covid-19. This article explains more about molnupiravir (Lagevrio) and sotrovimab (Xetrudy) and how to get them if you catch coronavirus.

In what they believe to be the first study of its kind, researchers investigated wayfinding skills - how we find our way between places - in people with MS.

This research, part of the UK MS Register Covid-19 study, investigated how well people with MS recover from mild to moderate Covid-19 and the factors that influence recovery.

Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium for people with relapsing remitting multiple sclerosis.